Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.

Rhomberg, Paul R.; Biedenbach, Douglas J.; Jones, Ronald N.

doi:10.1016/s0732-8893(01)00247-4

Cited by 16 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Piperacillin-tazobactam, imipenem, and the quinolones showed good activity against most species, as has been noted in other studies (6,12,15,21,25). Reduced activity to all of these agents was only found among isolates of B. vulgatus and B. thetaiotaomicron species.…”

Section: Discussionsupporting

confidence: 82%

“…It is effective in vitro against Staphylococcus aureus, Legionella sp., Campylobacter jejuni, and Helicobacter pylori (11,21). Among the quinolones, it has comparable activity to trovafloxacin and activity superior to those of other quinolones against anaerobes as demonstrated in this and other studies (15,21). Consequently, it could prove to be a useful agent for the treatment of anaerobic and polymicrobial infections, particularly in the nosocomial setting.…”

Section: Discussionmentioning

confidence: 64%

“…Garenoxacin (BMS-284756, T-3811 ME) is a novel des-F(6)-quinolone that lacks the 6-position fluorine but retains broad-spectrum activity against gram-positive and gram-negative pathogens as well as anaerobes (12,21). It has equivalent activity to trovafloxacin against gram-negative anaerobes and often superior activity against gram-positive anaerobes (21). It also has activity against anaerobes overall that is superior to those of levofloxacin and moxifloxacin (15).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Activities of Garenoxacin (BMS-284756) and Other Agents against Anaerobic Clinical Isolates

Hecht

Osmolski

2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

A total of 590 clinical isolates consisting of 33 species of both gram-positive and gram-negative anaerobes were collected from nine centers in the Chicago area in 1998-1999. The largest number of isolates (330 isolates, 56%) belonged to the Bacteroides group. Isolates were tested by agar dilution against garenoxacin (BMS-284756, T-3811 ME), trovafloxacin, moxifloxacin, clindamycin, imipenem, piperacillin-tazobactam, and cefoxitin. All but one species (2% of Bacteroides vulgatus isolates) were fully susceptible to piperacillin-tazobactam and imipenem. A number of species were resistant to clindamycin. Among the fluoroquinolones, garenoxacin and trovafloxacin had an MIC at which 90% of the isolates tested were inhibited of <4 g/ml for all but two species (Fusobacterium mortiferum/varium and Peptostreptococcus anaerobius).Anaerobic bacteria cause a variety of infections, in particular, abdominal surgical wound infections and periodontal disease. They also play a role in diabetic foot infections and gynecologic and obstetric infections caused by mixed aerobic and anaerobic bacteria (1). Therapeutic regimens include cephalosporins, aminoglycosides, quinolones, metronidazole, or clindamycin, depending on the source of the infection (13). However, several species are becoming increasingly resistant to cephalosporins due to the acquisition of beta-lactamases. A number of Prevotella species associated with periodontal disease have been found to be beta-lactamase positive (10). In a study of fecal anaerobic strains, resistance to ampicillin, cefoxitin, or cefuroxime was found in 70% of strains, with 19% showing multiple resistance to both ampicillin and cefuroxime (25). Resistance to clindamycin is also increasing (6), and as many as 20 to 40% of Bacteroides fragilis strains are clindamycin resistant (2,14). Although metronidazole is effective against gram-negative anaerobes, 31% of gram-positive anaerobes have been reported to be resistant (24).Newer respiratory quinolones such as gatifloxacin, moxifloxacin, trovafloxacin, clinafloxacin, and sitafloxacin show better antianaerobic activity than older quinolone compounds such as ciprofloxacin (3,7,27). Garenoxacin (BMS-284756, T-3811 ME) is a novel des-F(6)-quinolone that lacks the 6-position fluorine but retains broad-spectrum activity against gram-positive and gram-negative pathogens as well as anaerobes (12, 21). It has equivalent activity to trovafloxacin against gram-negative anaerobes and often superior activity against gram-positive anaerobes (21). It also has activity against anaerobes overall that is superior to those of levofloxacin and moxifloxacin (15).In this study, we determined the in vitro activity of garenoxacin and compared it with those of trovafloxacin, moxifloxacin, imipenem, clindamycin, piperacillin-tazobactam, and cefoxitin against 33 species of gram-positive and gram-negative anaerobic bacteria comprising 590 recent clinical isolates obtained from the Chicago, Ill., area. MATERIALS AND METHODSBacterial strains. Clinical isolates (590) collected fr...

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 64%

mentioning

confidence: 99%

See 1 more Smart Citation

Activities of Garenoxacin (BMS-284756) and Other Agents against Anaerobic Clinical Isolates

Hecht

Osmolski

2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Overall, the MICs of garenoxacin for 50 and 90% of the strains tested (in micrograms per milliliter) were as follows: Bacteroides fragilis group, 0.5 and 2; Prevotella spp., 0. 25 Resistance to ␤-lactams, clindamycin, and metronidazole among anaerobes is increasing worldwide (5,10,16,20,21,23). The older quinolones ciprofloxacin and levofloxacin provide only limited activity against many anaerobic species (7,8,11,14,28,31).…”

mentioning

confidence: 99%

“…It displays a high degree of in vitro activity against a broad range of gram-positive and gram-negative bacterial pathogens, including anaerobes (6,12,13,15,17,24,25,29,30).…”

mentioning

confidence: 99%